Background: This study investigated the predictive and prognostic significance of assessing early drug response with both positron-emission computerized tomography (PET-CT) and circulating tumor cells (CTCs) in patients receiving first-line chemotherapy for metastatic colorectal cancer.
Introduction
The early detection of response to anti-cancer therapy is important in the management of metastatic colorectal cancer (mCRC) and evaluation of investigational drugs. Currently, the most popular way of assessing drug response is to measure serial changes in tumor dimensions based on radiographic criteria such as the Response Evaluation Criteria in Solid Tumours (RECIST). However, this approach requires the patient having completed at least several cycles of chemotherapy in order to detect any tumor shrinkage [1] . Another approach is to measure drug response based on tumor metabolic activity with 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET), and several response criteria have been developed for solid tumors. These include the European Organisation for Research and Treatment of Cancer (EORTC) and the 'PET Response Criteria in Solid Tumors' (PERCIST) criteria [2, 3] . Specifically in patients with mCRC, the studies reported to date concerning PET response to chemotherapy are relatively small in terms of sample size. Although the sensitivity of PET in predicting subsequent RECIST response was reported to be very high (100%) in some of these studies, the specificity was only 53-57% [4, 5] . Besides imaging, the detection of circulating tumor cells (CTC) in peripheral blood has also been prospectively evaluated as a predictive biomarker, but its sensitivity of predicting subsequent RECIST response is relatively low at $30% [6] . Given the respective limitations of PET and CTC, the primary objective of this study was to investigate if the combined assessment of PET-CT and CTC could yield additional prognostic information at an earlier time-point during treatment than either modality alone. The secondary objective was to investigate if adding CTC to PET-CT could better predict the subsequent RECIST response than with either modality alone in patients with mCRC.
Methods

Patient enrollment
This was a single institutional study where eligible patients had to be aged 18 years or above with an Eastern Cooperative Group (ECOG) performance status of 0-2, and were medically fit for chemotherapy and able to give written informed consent. They all had treatment-naive mCRC that were measurable by RECIST criteria (version 1.1), and were not amenable to potentially curative treatment. Enrolled patients were required to undergo first-line chemotherapy with a fluoropyrimidine-based regimen in combination with oxaliplatin or irinotecan at the physician's discretion.
Study procedure
The study procedures were performed at 3 time-points. Prior to starting treatment, all patients had a whole-body and contrast-enhanced PET-CT and CTC analysis (7.5 ml of blood). At 4-6 weeks after starting chemotherapy, all patients had a whole-body PET-CT (plain CT scan) and CTC analysis; and at 10-12 weeks, they all had a contrast-enhanced CT scan of the thorax, abdomen and pelvis.
Radiographic imaging acquisition, analysis and interpretation
The PET-CT scans were performed with a single imaging system (Philips GEMINI GXL PET-CT Imaging System, Phillips Medical Systems, Netherlands) under identical conditions as previously described [7] . The CT component of the PET-CT scanner was a 16-slice multi-detector CT scanner (Philips Medical Systems International BV). The contrastenhanced CT scan at 10-12 weeks after starting chemotherapy was performed on a separate helical CT scanner (VCT, General Electric Medical Systems, Milwaukee, WI) [8] .
The PET images (with and without attenuation correction), CT images and the PET-CT fusion images were interpreted in parallel. Visual assessment and semi-quantitative assessment of the regions of interest (ROI) were made by measuring the SUVmax normalized to injected activity and the patient's body weight at the initial 60-min PET image acquisition. A delayed PET-CT scan was performed when there were equivocal findings such as increased 18F-FDG uptake without the presence of a focal mass, or a radiologically suspicious lesion that had low SUVmax. At baseline, target lesions with the highest 18F-FDG uptake in as many involved organ systems as applicable were first selected from the PET-CT scans, based on the criteria that ROIs with a SUVmax value of >2.0 were regarded as pathological, and a maximum of 10 target lesions were selected per patient per scan, with a maximum of five lesions per organ. Then, the dimensions of the same target lesions were measured from the simultaneously acquired contrast-enhanced CT images according to the RECIST criteria (version 1.1). The same target lesions were assessed on all the follow-up PET (plain) and CT (contrast) scans, respectively. Although the EORTC criteria did not specify the total number of target lesions to be chosen per scan [2] , three studies conducted in mCRC patients studies used anywhere between three to all detectable lesions in their analyses [9] [10] [11] . In the current study, an arbitrary number of 10 lesions per scan was used.
Determination of circulating tumor cells level
Peripheral blood mononuclear cells (PBMCs) were prepared from 7.5 ml of blood using Ficoll-Paque Plus (GE Healthcare, UK), CTCs were then isolated and detected using the Carcinoma Cell Enrichment and Detection Kit (Miltenyi Biotech, Germany) according to the manufacturer's instructions (see supplementary files for detail, available at Annals of Oncology online).
The criteria used to identify a positive CTC in a blood sample were as follow: cells should display positive bright red staining, have a round-tooval morphology and at least twice the size of a lymphocyte. All CTCs were examined under a microscope at 200Â magnification and quantified by two independent assessors who were blinded from the patients' clinical information. Any discrepant result in a CTC sample would be reexamined independently until a consensus could be reached [12] .
Study endpoints and statistics
The primary objective of this study was to determine if measuring both early PET response and CTC level (known thereafter as the 'dualendpoint') at 4-6 weeks after starting chemotherapy, could better predict progression-free survival (PFS) or overall survival (OS) than either modality alone in patients undergoing chemotherapy for mCRC. The secondary objective was to determine if this dual-endpoint could better predict the subsequent RECIST response at 10-12 weeks after starting chemotherapy than either modality alone. This study also explored the prognostic and predictive significance of tumor metabolic activity and the level of CTC at baseline, and to determine whether the level of CTC at 4-6 weeks after treatment could predict RECIST response when compared with serum carcinoembryonic antigen level (CEA). OS was defined as the time from study registration to death due to any cause, and PFS was defined as the time from study registration to the first event of cancer progression or death due to cancer or other causes.
In this study, early PET response was defined as !30% drop in the sum of SUVmax values of all target lesions that were assessed at 4-6 weeks after starting chemotherapy. There is currently no consensus over the optimal cut-off in the percentage change of SUVmax values post-treatment in mCRC [4, 5, 13, 14] . The EORTC criteria recommends a decline of >25% after more than one cycle of chemotherapy [2] , while the PERCIST criteria suggested that a post-treatment decline of 30% as most clinically relevant [3] . In the current study, a cut-off threshold of 30% decline in SUVmax value was found to be most significant in a multivariate analysis. Regarding the CTC criteria, a clinically relevant CTC response is defined as the detection of a CTC level of <3 cells per 7.5 ml of blood at 4-6 weeks after starting chemotherapy. This cut-off was chosen because two prospective studies have reported that this cut-off was prognostic in mCRC [15, 16] .
The sample size was calculated based on the hypothesis that that the dual endpoint could distinguish a difference in PFS of 'non-responders' versus 'responders' to chemotherapy. There are very few reports that directly compared the treatment outcome of responders versus nonresponders to first-line chemotherapy in mCRC [17, 18] . The hazard ratios for survival or progression reported in these reports varied widely from 0.90 to 0.27 among drug responders [17, 18] . Therefore, this study arbitrarily postulated that the median PFS of non-responders could be approximately half of that for responders-9 months versus 18 months, respectively, and thus the HR for PFS was estimated to be $2-2.2. Assuming that PFS follows an exponential distribution, the study needed to recruit 68 patients to detect the difference between two groups with two-sided alpha level of 0.05 and the power of 0.8. Assuming a 10% of withdrawal rate, $76-80 patients would be needed.
Data analysis
The Cox Proportional Hazard Model was used to estimate the hazard ratio and the 95% confidence interval (CI). A multivariate analysis was performed to adjust for the effect of the key prognostic variables including PET response alone, CTC response alone, the dual endpoint and RECIST response at 10-to 12-week post-treatment pre-treatment SUVmax or CTC level). Other covariates included were age, gender, number of sites of metastases, pre-treatment level of CTC or sum of SUVmax values of target lesions, use of oxaliplatin or irinotecan and the concomitant use of monoclonal antibodies). Survival was estimated using the Kaplan-Meier method and log-rank test was used to compare survival curves.
Correlation between RECIST response and a number of predictive factors were analyzed with the chi-square test, these included the dualendpoint, pre-treatment level of SUVmax (sum of values of target lesions), CTC and serum CEA level; the post-treatment level of SUVmax (sum of values of target lesions, using a cut-off of 30%), CTC (using a cut-off of 3 cells per 7.5 ml of blood) and CEA level. The sensitivity, specificity and positive predictive value (PPV) for predictive factors (such as PET response and dual endpoint) to RECIST response were calculated and the corresponding Area Under the Curve (AUC) was computed.
A P value of <0.05 was regarded as statistically significant. This study was approved by the Institutional Ethics Committee, and all enrolled subjects had to give written informed consent.
Result
A total of 84 patients were recruited from the Prince of Wales Hospital (Hong Kong), and 83 patients who had undergone the baseline PET-CT and CTC analysis were included in the data analysis. Seventy-four patients who had completed the week 4 PET and CTC analysis were evaluated for dual endpoint (i.e. the primary endpoint), while 70 patients had completed all the planned procedures in this study (>80% of enrolled subjects). The main reason for not completing all of the assessments was clinical deterioration . The clinical characteristics of the enrolled subjects are summarized in Table 1 . At a median follow-up of 32.9 months (95% CI ¼ 24.5 months-not reached), 78 patients had died or progressed. For the entire cohort, the median PFS was 6.24 months (95% CI ¼ 5.46-6.95 months) and the median OS was 13.3 months (95% CI ¼ 10.5-17.8 months). Table 2 outlines the result of drug response based on different criteria.
Prognostic association
In the univariate analysis, PFS was significantly associated with RECIST response, CTC level of <3 cells/7.5 ml of blood at 4-6 weeks, the dual endpoint, number of sites of metastases and the use of oxaliplatin (see supplementary Table S1 , available at Annals of Oncology online). There was a non-significant trend toward an association between PFS and SUVmax drop of !30% at 4 weeks. In the multivariate analysis, two variables remained significant: the dual endpoint (HR ¼0.452, 95% CI: 0.267-0.765, P ¼ 0.0031) and the number of sites of metastases (HR ¼1.959, 95% CI: 1.163-3.302, P ¼ 0.0116). Figure 1 showed the PFS curves of patients who achieved the dual response endpoint (median PFS ¼ 7.41 months, 95% CI: 6.05-9.11) versus those who did not (median PFS¼ 5.37 months, 95% CI: 4.68-6.24, P ¼ 0.0167 by log-rank test).
Regarding the association with OS in the univariate analysis, there was a non-significant trend of association with RECIST response and a significant association with baseline SUVmax. In the multivariate analysis, RECIST response was the only significant predictor of OS (HR ¼0.484, 95% CI: 0.275-0.852, P ¼ 0.0119). Figure 2 shows the OS curves of patients who had a RECIST response (median OS ¼ 19.68 months, 95% CI: 13.89-23.74 months) and those who had not (median OS ¼ 10.5 months, 95% CI: 7.54-13.33 months, log-rank P ¼ 0.055) (see supplementary Table S2 , available at Annals of Oncology online).
Predictive association
The probability of achieving a RECIST response at 10-12 weeks after chemotherapy was significantly associated with early PET response (P ¼ 0.0045, chi-square) and the dual response endpoint (P ¼ 0.005, chi-square). There was no correlation between RECIST response at 10-12 weeks with the levels of CTC and CEA obtained before treatment or at 4-6 weeks after chemotherapy. The accuracy of PET response alone in predicting a RECIST response is represented by a sensitivity of 79%, specificity 53% and a positive predictive value (PPV) of 69%. The addition of CTC to PET as the dual endpoint resulted in a sensitivity of 64%, specificity of 70% and a PPV of 74%. The Area under the Curve (AUC) for the PET response and the dual endpoint were 0.6641 and 0.6705, respectively. There was no statistical difference in the AUC between PET response and the dual endpoint.
Discussion
This study met its primary endpoint of demonstrating that the combination of CTC to PET-CT assessment at 4-6 weeks after starting chemotherapy could better predict PFS than if either modality was used alone to assess response to chemotherapy in patients with mCRC. However, there was no statistical association between the dual endpoint and OS. This meant that subjects who achieved the dual endpoint at 4-6 weeks after chemotherapy had longer PFS (but not OS). Regarding the secondary endpoint, subjects who achieved the dual endpoint at 4-6 weeks were more likely to achieve a RECIST response at 10-12 weeks than those who did not. However, although the addition of CTC to PET-CT appeared to predict RECIST response with a high specificity and positive predictive value than with PET-CT alone, there was no statistical difference when PET alone was compared with the dual endpoint using the AUC method.
This study found that RECIST response was predictive of OS, while other factors such as PET response, CTC response or the dual endpoint did not reach statistical significance. The evidence behind the association of early tumor shrinkage and OS is conflicting in the literature on mCRC. This association maybe relevant in RAS-wild type patients receiving epidermal growth factor receptor (EGFR) antibodies [19] , but may not be for patients receiving chemotherapy alone or with vascular endothelial growth factor antibody [20] . The current study was not designed to test if the dual endpoint is preferable over RECIST criteria for assessing response to all types of anti-cancer drugs. This study was designed to see if PET-CT and CTC together as a dual endpoint could be an early indicator of the subsequent RECIST response. This dual endpoint could be a useful tool in determining early drug response in clinical trials of novel agents where the predominant effect is on slowing progression rather than inducing early tumor shrinkage. Moreover, it could be investigated in settings where an early knowledge of drug response may change a patient's management-such as neoadjuvant chemotherapy for inoperable liver metastases.
Currently, there is no consensus with regards to the optimal percentage decline in SUVmax values when determining early PET response in mCRC, and published studies have suggested that an early SUVmax decline of 15-50% at the disease sites as CR, complete response; PR, partial response; NE, not evaluable due to failure to complete study investigation. being prognostic and predictive of tumor response [5, 9, 13, 14] . Hendlisz et al. found that a 15% cut-off SUVmax value was associated with a relatively low specificity of 57% and a PPV of 43% [5] , but in a subsequent consensus report by Wahl et al., a more stringent minimum cut-off value of 30% decline in SULpeak (SUV adjusted to lean body mass) was preferred [3] . The current study adopted 30% decline in SUVmax as an indicator of PET response, and this seems to be associated with a relatively higher PPV of 74% than that reported by Hendlisz et al. [5] .
Numerous PET parameters have been studied, but there is no general consensus as which one should be preferred over the others [9, 21, 22] . These included SUVmax-based parameters (e.g. Total SUVmax of all target lesions, Highest SUVmax in one lesion, SUVpeak, SUVmean, SULpeak), volumetric-based parameters (e.g. Metabolic Tumor Volume, MTV; Total Lesion Glycolysis (TLG) and others. Two studies which compared different PET metrics and RECIST criteria in assessing response of liver metastases to chemotherapy or SIRT in patients with mCRC, have found conflicting results over the performance of SUVmax versus TLG or MTV [9, 21] . Studies which compared the EORTC and PERCIST criteria have found that they agreed closely in defining tumor response and predicting survival [10, 23] . Therefore, the literature suggests that FDG-PET does provide prognostic information in patients undergoing chemotherapy, irrespective of which parameters and criteria are used.
In a meta-analysis of 11 studies on the prognostic evaluation of CTC as determined by the CellSearch TM system (Janssen Diagnostics, LLC, NJ), cut-off values of !3 cells per 7.5 ml of blood have been consistently associated with poorer survival [6] . To date, there is little scientific basis and consensus on the optimal sampling time [24] , and in a meta-analysis CTC is prognostic regardless of whether the samples were obtained at baseline or at various intervals post-treatment [25] .
In contrast to the studies which used an automated enumeration system [15, 26] , the current study used manual enumeration and the Miltenyi Biotech platform, where the detection rate of CTC at baseline was 39.8% (33 out of 83 patients) [12] . This is comparable to the detection positivity rate of the CellSearch TM system, which has been reported by Cohen et al. to be between 33% and 48% in mCRC [16] . Furthermore, the percentage of patients with 'unfavorable' CTC level at baseline in this study (24%, 20 out of 83 patients) was very similar to that reported by Cohen et al. (26%) [16] . Using the same method for detecting CTCs as in the current study, the authors have been able to find statistically significant correlations between CTC and survival in patients with CRC [27] . Furthermore, Lighthart et al. found that a manual assessment of archived CTC images acquired from the Cellsearch TM platform, correlated with a fully automated algorithm in patients with CRC and other cancers, in predicting survival and assessing the CTC level [28] . Therefore, the literature supports the prognostic significance of CTC irrespective of the platform used to enumerate CTC.
Conclusion
This study showed that early assessment of response to chemotherapy using a combined approach of PET-CT and CTC analysis at 4-6 weeks after starting chemotherapy has prognostic and probably predictive significance in the first-line treatment of patients with mCRC. This novel dual response criterion has potential application in the evaluation of new drugs and in influencing treatment decisions at earlier time-points during chemotherapy.
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